NCCN Guidelines Revisions and ASCO 2024 Research Outlook

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer

EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024

EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib

EP: 6.Exploring Results from CAPItello-291 Trial

EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer

Now Viewing

EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook

EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts

1. How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
2. What data, results, or insights are you looking forward to coming out of ASCO 2024?

Related Videos

Related Content

Advertisement

January 16th 2025

High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer

Brooke McCormick

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 15th 2025

ACCC Helps Share Best Practices for MPN Care

Mary Caffrey

Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality improvement initiative in myeloproliferative neoplasms (MPNs).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 15th 2025

Patients With HIV May Have High Prevalence of Long COVID

Julia Bonavitacola

Although the association between HIV and long COVID was inconclusive, the prevalence of long COVID in patients with HIV was high.

January 14th 2025

Niraparib Improves Outcomes in Patients With Stage III EOC, No Visible Residual Disease

Brooke McCormick

Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.

Related Content

Advertisement

January 16th 2025

High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer

Brooke McCormick

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 15th 2025

ACCC Helps Share Best Practices for MPN Care

Mary Caffrey

Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality improvement initiative in myeloproliferative neoplasms (MPNs).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 15th 2025

Patients With HIV May Have High Prevalence of Long COVID

Julia Bonavitacola

Although the association between HIV and long COVID was inconclusive, the prevalence of long COVID in patients with HIV was high.

January 14th 2025

Niraparib Improves Outcomes in Patients With Stage III EOC, No Visible Residual Disease

Brooke McCormick

Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.